Die Gründung eines innovativen Unternehmens stellt eine Form der kommerziellen Verwer-tung von Wissen dar. Der Beitrag gibt einen Überblick über Ausmaß von Gründungen in wis-sensintensiven bzw. innovativen Branchen und deren Entwicklung. Da die Gründung eines Unternehmens wesentlich durch...

Die Rolle der Hochschulen im Innovationssystem sowohl der BRD als auch der DDR hat sich in den letzten fünfzig Jahren zum Teil dramatisch geändert. Der Veränderungsprozess in der Bundesrepublik lässt sich grob in drei Phasen einteilen, die sich zwar überlappen, dennoch im wesentlichen eine...

Audretsch and Fritsch (2002) proposed two explanations for the mixed evidence regarding the relationship between new firm formation and regional development. Firstly, they found evidence for the existence of long time lags needed before the main effects of new firm formation on employment change...

This study is framed against the increasingly stringent environmental demands on the pulp and paper industry since the late-1980s to reduce water and air pollution, and the global economic slowdown of the early-1990s. The primary focus of this paper is an observation-based analysis conducted by...

The paper aims at assessing discrete complementarities in innovation policies in the context of the Brazilian industry in 2003. The paper considers the approach advanced by Mohnen and and Röller [European Economic Review, 2005] that focuses on supermodularity and submodularity tests for...

Using a German firm-level data set, this paper is the first to jointly study the cyclical properties of the cross-sections of firm-level real value added and Solow residual innovations, as well as capital and employment adjustment. We find two new business cycle facts: 1) The cross-sectional...

Is time-varying firm-level uncertainty a major cause or amplifier of the business cycle? This paper investigates this question in the context of a heterogeneous-firm RBC model with persistent firm-level productivity shocks and lumpy capital adjustment, where cyclical changes in uncertainty...

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...